
|Videos|July 17, 2020
Glaucoma 360: Drug delivery contact lens technology
Author(s)Alex Delaney-Gesing
ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface disease, during the 2020 Glaucoma 360 meeting in San Francisco, California.
Advertisement
ICYMI: Chris Adams, CEO of Diopter Corp, discusses the company's drug delivery contact lens technology in the pipeline that works to treat ocular surface diseases, during the 2020 Glaucoma 360 meeting in San Francisco, California.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
2
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
3
First patient treated in ViaLase’s IDE trial
4
Study maps thermal dynamics of glaucoma laser treatments
5















































.png)


